Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
文献类型：期刊论文
| 作者 | Sun, Yongkun44; Zhang, Wen44 ; Bi, Xinyu43; Yang, Zhengqiang42; Tang, Yu41; Jiang, Liming40; Bi, Feng39; Chen, Minshan38; Cheng, Shuqun37; Chi, Yihebali44
|
| 刊名 | LIVER CANCER
 |
| 出版日期 | 2022-06-01 |
| 卷号 | 11 |
| ISSN号 | 2235-1795 |
| 关键词 | Chinese interdisciplinary experts Hepatocellular carcinoma Molecular targeted therapy Consensus |
| DOI | 10.1159/000521596 |
| 通讯作者 | Zhao, Hong(zhaohong@cicams.ac.cn) ; Zhou, Aiping(aiping_zhou@yeah.net) ; Cai, Jianqiang(caijianqiang188@sina.com) |
| 英文摘要 | Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals. |
| WOS关键词 | VEIN TUMOR THROMBUS ; TRANSARTERIAL CHEMOEMBOLIZATION ; LIVER-TRANSPLANTATION ; DOUBLE-BLIND ; 1ST-LINE TREATMENT ; PLUS SORAFENIB ; OPEN-LABEL ; PHASE-III ; EFFICACY ; SAFETY |
| 资助项目 | State Key Project on Infection Diseases of China[2017ZX10201021-007-003] ; CAMS Innovation Fund for Medical Sciences (CIFMS)[2017-12M-4-002] ; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences[2019PT310026] ; Sanming Project of Medicine in Shenzhen[SZSM202011010] ; Capital Health Research and Development of Special[2018-1-4021] |
| WOS研究方向 | Oncology ; Gastroenterology & Hepatology |
| 语种 | 英语 |
| 出版者 | KARGER |
| WOS记录号 | WOS:000840263800002 |
| 资助机构 | State Key Project on Infection Diseases of China ; CAMS Innovation Fund for Medical Sciences (CIFMS) ; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences ; Sanming Project of Medicine in Shenzhen ; Capital Health Research and Development of Special |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/132071]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Zhao, Hong; Zhou, Aiping; Cai, Jianqiang |
| 作者单位 | 1.Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiol, Tai An, Shandong, Peoples R China 2.Chinese Univ Hong Kong, Dept Hepat Biliary Pancreat Surg, Hong Kong, Peoples R China 3.Fudan Univ, Dept Liver Surg, Zhongshan Hosp, Shanghai, Peoples R China 4.Beijing Tsinghua Changgung Hosp, Dept Hepatopancreatobiliary Surg, Beijing, Peoples R China 5.Peking Univ First Hosp, Dept Intervent Radiol, Beijing, Peoples R China 6.Beijing Canc Hosp, Dept Intervent Radiol, Beijing, Peoples R China 7.Harbin Med Univ Canc Hosp, Dept Oncol, Harbin, Peoples R China 8.Second Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China 9.Fudan Univ, Dept Radiol, Zhongshan Hosp, Shanghai, Peoples R China 10.Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Sun, Yongkun,Zhang, Wen,Bi, Xinyu,et al. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements[J]. LIVER CANCER,2022,11. |
| APA | Sun, Yongkun.,Zhang, Wen.,Bi, Xinyu.,Yang, Zhengqiang.,Tang, Yu.,...&Cai, Jianqiang.(2022).Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.LIVER CANCER,11. |
| MLA | Sun, Yongkun,et al."Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements".LIVER CANCER 11(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。